Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following adverse reactions are ...
It is the brand name ofaripiprazole, a psychotropic medication that alters brain chemical activity by blocking the receptors on nerves in the brain. This medication was first approved by the US Food and Drug Administration in 2002 to treat schizophrenia in children ages 13 and older and adults. ...
ABILIFY activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D2receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma. The...
The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis. 5.2 ...
Secondary outcomes (social and occupational functioning and illness severity) and adverse drug reactions (ADR) were also assessed.A majority of the 169 evaluable patients were within the first 5years of diagnosis (early phase). A linear mixed model analysis showed a significant main effect of time...
Our Abilify Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. WARNING INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS ...
If signs and symptoms of tardive dyskinesia appear in a patient treated with ABILIFY ASIMTUFII, drug discontinuation should be considered. However, some patients may require treatment with ABILIFY ASIMTUFII despite the presence of the syndrome. 5.5 Metabolic Changes Atypical antipsychotic drugs have ...
ABILIFY MYCITE, a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion, is indicated for the: Treatment of adults with schizophrenia. Treatment of bipolar I disorder ...